- βThe reduced-intensity HSCT approach showed a promising efficacy signal, with 43% of transplant patients achieving endoscopic remission vs. 0% in standard care
- βThe trial used a lower-dose chemotherapy regimen than prior HSCT studies, representing a meaningful attempt to improve the safety profile
- βEarly halting of the trial protects future patients and provides critical safety data that will inform the design of safer protocols going forward
| Country | UK |
| Journal | The lancet. Gastroenterology & hepatology |
| Year | 2024 |
| Authors | Lindsay, Hind, Swaby |
| PMID | 38340759 |
UK Stem Cell Trial for Crohn's Disease Halted Over Safety Concerns
A study from the United Kingdom has delivered an important β and sobering β finding for patients with severe, treatment-resistant Crohn's disease: a stem cell transplant approach that researchers hoped would reset the immune system proved too dangerous for widespread use. The ASTIClite trial, conducted across nine National Health Service (NHS) hospitals in the UK, was halted early after a series of life-threatening complications, including two patient deaths.
What the Researchers Were Trying to Do
Crohn's disease is a chronic inflammatory bowel condition that, in its most severe forms, stops responding to even the most advanced biologic medications. For these patients β sometimes called "refractory" β treatment options become desperately limited. UK researchers at Queen Mary University of London explored whether autologous haematopoietic stem cell transplantation (HSCT) could offer a solution.
In this procedure, a patient's own stem cells are harvested, the immune system is effectively wiped out using chemotherapy drugs (cyclophosphamide and fludarabine), and the stem cells are reinfused to essentially reboot immune function. The ASTIClite trial used a lower-intensity version of this approach compared to prior attempts, hoping to reduce toxicity while maintaining effectiveness.
What the Study Found
Of the 23 patients enrolled between 2018 and 2019, 13 were assigned to the stem cell transplant group and 10 received standard care (continued biological, conventional, or nutritional therapy). The trial was stopped early after six patients in the transplant group experienced nine serious unexpected adverse reactions, including:
- Renal (kidney) failure due to thrombotic microangiopathy in three patients
- One in-trial death from pulmonary veno-occlusive disease (a dangerous lung condition)
- A second death after the study period ended, from respiratory and renal failure
On the efficacy side, 43% of evaluable transplant patients showed no endoscopic ulceration at 48 weeks β a meaningful result β compared to 0% in the standard care group. However, every single patient in the transplant group (100%) experienced at least one serious adverse event, versus 40% in the standard care group.
Why This Matters for US Patients
In the United States, approximately 780,000 Americans live with Crohn's disease. Current treatment guidelines from the American College of Gastroenterology (ACG) recommend a stepwise approach β from aminosalicylates to immunomodulators to biologics such as TNF inhibitors (adalimumab, infliximab), IL-12/23 inhibitors (ustekinumab), and integrin blockers (vedolizumab). For patients who fail multiple biologic classes, options narrow significantly.
Some US patients with refractory Crohn's may wonder whether stem cell transplantation β occasionally discussed in specialist circles or found through online research β could be their answer. This UK trial is a critical reminder that even a "reduced intensity" version of HSCT carries potentially fatal risks. The trial's early termination signals that this particular regimen should not be pursued in clinical practice.
That said, the partial efficacy signal is not meaningless. Researchers will likely continue refining transplant protocols. For now, US patients with refractory Crohn's are encouraged to discuss enrollment in clinical trials, newer biologic combinations, or surgical options with their gastroenterologist before considering experimental immune-reset therapies.
The Bottom Line
This UK study underscores a universal truth in medicine: a treatment that works imperfectly but safely may be far preferable to one that works better but harms. For American patients battling severe Crohn's disease, this research reinforces the importance of working closely with a specialist to explore all approved therapies before pursuing high-risk experimental options.
Source: Lindsay J, Hind D, Swaby L, et al. "Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite)." The Lancet Gastroenterology & Hepatology. 2024. DOI: 10.1016/S2468-1253(23)00460-0. PMID: 38340759.